Journal
DRUG RESISTANCE UPDATES
Volume 8, Issue 5, Pages 298-310Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.drup.2005.08.004
Keywords
epidermal growth factor receptor; EGFR; molecular-targeted cancer therapy; small molecule tyrosine kinase inhibitors; monoclonal antibodies; non-small cell lung cancer
Categories
Funding
- NCI NIH HHS [R01 CA109520-01, R01 CA100816-01] Funding Source: Medline
Ask authors/readers for more resources
The epidermal growth factor receptor (EGFR) has been a major target of molecular anticancer therapy. Two approaches have been developed, involving monoclonal antibodies and receptor tyrosine kinase inhibitors, and both have demonstrated benefit in clinical trials. However, evidence of resistance to these drugs has been described. Cellular levels of EGFR do not always correlate with response to the EGFR tyrosine kinase inhibitors, indicating acquired resistance to these drugs. Since EGFR antagonists interfere with the activation of several intracellular pathways that control cell proliferation, survival, apoptosis, angiogenesis, invasion and metastasis, acquired resistance can occur as a result of several different molecular mechanisms: autocrine/paracrine. production of ligand, receptor mutation, constitutive activation of the downstream pathway and activation of alternative pathways. We will describe here potential mechanisms that can cause resistance to EGFR-targeted drugs. Combinations of EGFR antagonists with inhibitors targeting different signaling mechanism(s)-such as insulin-like growth factor receptor and vascular endothelial growth factor receptor-that share the same downstream mediator (e.g., phosphatidylinositol 3-kinase/Akt, mitogen-activated protein kinase), may circumvent or delay the development of resistance to EGFR antagonists resulting in enhanced antitumor activities. (C) 2005 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available